Newsletter
NEWS AND EVENTS
Home
Company
PIPELINE AND PORTFOLIO
Investor Relations
News and Events
Contact
Privacy Policy
Disclaimer
Imprint
Archive Press
© relief therapeutics 2025
Latest News
Stay up to date on Relief activities
Corporate News
Archive
Relief Therapeutics Convenes Extraordinary General Meeting
24 October 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination
08 October 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Publishes 2025 Half-Year Report
14 August 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Advances Publication of 2025 Half-Year Report
11 August 2025 | non-Ad Hoc
Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze
29 July 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
20 June 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Results of Annual General Meeting
12 June 2025 | non-Ad Hoc
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
22 May 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
15 May 2025 | non-Ad Hoc
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
10 April 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
06 March 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
11 February 2025 | non-Ad Hoc
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
22 January 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
27 December 2024 | non-Ad Hoc
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
16 December 2024 | non-Ad Hoc
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
13 December 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
11 November 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
04 November 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
29 October 2024 | non-Ad Hoc
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
25 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Company
Pipeline
Investor Relations
News and Events
© Relief Therapeutics